Brolucizumab Prevails in Treat-and-Extend Trial of Anti-VEGF Therapy for Eye Disease

MedPage Today) — NEW YORK CITY — The monoclonal antibody brolucizumab (Beovu) significantly extended the treatment-free interval without disease activity for neovascular age-related macular degeneration (nAMD), with comparable visual acuity…
Read More